Prognostic Value of Prothrombin Fragments 1+2 for Pulmonary Embolism Incidence
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Contacts and Locations
Study Locations
-
-
-
Hadera, Israel, 38100
- Hillel Yaffe Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- COPD exacerbation
- Able to give informed consent
- Able to perform spirometry
Exclusion Criteria:
- Known malignancy
- Known hypercoagulable state
- Receiving anticoagulant treatment
- Pregnancy
- Renal failure
- Allergy to Iodine
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
COPD exacerbation
Patients admitted to hospital with COPD exacerbation
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 0001-10
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Disease, Chronic Obstructive
-
NCT03745547CompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary Disease
-
NCT06629675RecruitingChronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Lung Disease | Chronic Obstructive Airway Disease
-
NCT04828837TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With Exacerbation
-
NCT05431218CompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease Severe
-
NCT05539547Not yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
NCT02962999CompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease Mild
-
NCT03398772UnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End Stage
-
NCT05029349RecruitingChronic Obstructive Pulmonary Disease Severe
-
NCT05016466Not yet recruitingCOPD, Chronic Obstructive Pulmonary Disease
-
NCT04386590RecruitingChronic Obstructive Pulmonary Disease Moderate
Clinical Trials on CT pulmonary angio, blood tests
-
NCT01626521UnknownChronic Obstructive Pulmonary Disease | Pulmonary Embolism
-
NCT04002765RecruitingRheumatoid Arthritis
-
NCT02875444CompletedAbdominal Aortic Aneurysm
-
NCT04416100UnknownCovid-19 | Pulmonary Fibrosis
-
NCT02735746CompletedBreast Cancer | Lung Cancer | Radiation Pneumonitis | Mediastinum Lesion
-
NCT04405544CompletedCOVID | Encephalopathy
-
NCT03931356CompletedRadiotherapy; Complications | Cancer, Lung
-
NCT02779595CompletedRespiratory Insufficiency | Atelectasis | Pulmonary Infection | Bronchospasm | Aspiration Pneumonitis
-
NCT02419196CompletedPneumothorax | Respiratory Insufficiency | Pleural Effusion | Atelectasis | Pulmonary Infection | Bronchospasm | Aspiration Pneumonitis